- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Immune Checkpoint Inhibitors for Cancer Treatment Tied to Significant Reduction of Actinic Keratoses: JAMA

Australia: Researchers have found in a small study that immune checkpoint inhibitors (ICIs) used for cancer treatment significantly reduced actinic keratoses. The effect was most pronounced in younger patients and those with a history of blistering sunburn. In some cases, the preventive benefit persisted even after discontinuing treatment.
These findings, published in JAMA Dermatology, suggest that ICIs may serve as an immuno-preventive strategy for high-risk individuals.
The researchers note that keratinocyte carcinomas (KCs), including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common human cancers. Actinic keratoses (AKs) are precursors to cSCC, with a higher risk in patients with extensive lesions due to field cancerization. Immune checkpoint inhibitors improve survival, however, their preventive potential remains uncertain. Considering this, Charlotte Cox, University of Queensland, Brisbane, Australia, and colleagues aimed to assess the impact of immune checkpoint inhibitors (ICIs) on field cancerization by comparing the number of AKs and KCs at baseline and 12 months after initiating ICI therapy.
For this purpose, the researchers conducted a prospective cohort study at a tertiary public hospital in Brisbane, Australia, from April 2022 to November 2023. Immunocompetent adults initiating programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PDL-1) inhibitor therapy for active cancer, with a planned treatment duration of at least six months and clinical actinic keratoses on their forearms, were included. Those with immunosuppression, concurrent chemotherapy or radiotherapy, or recent topical fluorouracil use were excluded.
AKs were counted and photographed at baseline and three, six, and twelve months, while keratinocyte carcinoma numbers were assessed using histopathology reports. Participants’ medical history, cancer response, and adverse events were recorded.
Key Findings:
- The study included 23 participants, with 73.9% being male and a mean age of 69.7 years.
- No participants withdrew, but four died due to disease progression.
- The mean number of actinic keratoses (AKs) significantly decreased from 47.2 at baseline to 14.3 at 12 months.
- Younger patients were more likely to reduce AKs by 65% or more (66.7% versus 33.3%).
- Patients with a history of blistering sunburn had a 100% likelihood of reducing AKs by 65% or more.
- Total keratinocyte carcinoma (KC) numbers decreased from 42 before ICI therapy to 17 in the year after.
- Cutaneous squamous cell carcinoma cases declined from 16 to 5 over the same period.
“These findings suggest that immune checkpoint inhibitors, originally used for cancer treatment, may help mitigate field cancerization as an immunopreventive strategy in high-risk populations,” the researchers stated. They further noted, “While ICIs significantly reduced clinical actinic keratoses (AKs), the decline in cutaneous squamous cell carcinomas was not statistically significant.”
Concluding their findings, they emphasized, “Given the potential for life-threatening adverse events, these results highlight the need for future clinical trials to explore ICIs’ role in preventing keratinocyte carcinomas in individuals at extreme risk, particularly when other preventive options are not feasible.”
Reference:
Cox C, Brown S, Walpole E, et al. Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention. JAMA Dermatol. Published online February 12, 2025. doi:10.1001/jamadermatol.2024.5750
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751